U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C24H19ClN4O4.ClH
Molecular Weight 499.346
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BMS-908662 hydrochloride

SMILES

Cl.COC(=O)NC1=NC2=C(N1)C=CC(=C2)C3(O)N(C(=O)C4=CC=CC=C34)C5=C(C)C=CC(Cl)=C5

InChI

InChIKey=ACFCZHQPGRDESJ-UHFFFAOYSA-N
InChI=1S/C24H19ClN4O4.ClH/c1-13-7-9-15(25)12-20(13)29-21(30)16-5-3-4-6-17(16)24(29,32)14-8-10-18-19(11-14)27-22(26-18)28-23(31)33-2;/h3-12,32H,1-2H3,(H2,26,27,28,31);1H

HIDE SMILES / InChI

Molecular Formula C24H19ClN4O4
Molecular Weight 462.885
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

BMS-908662 (previously known as XL281) is a small molecule Raf kinase inhibitor that lies immediately downstream of RAS and are key components of the RAS/RAF/MEK/ERK kinase-signaling pathway. Bristol-Myers Squibb has received an exclusive worldwide license to develop and commercialize antineoplastic agent XL281. BMS-908662 participated in phase I development for the treatment of patients with melanoma and in combination with cetuximab for patients with colorectal cancer. However, further, development has been discontinued.

Approval Year

PubMed

PubMed

TitleDatePubMed
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors.
2015-04
Clinico-morphological features of BRAF inhibition-induced proliferative skin lesions in cancer patients.
2015-01-01
Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor.
2014-01
Patents

Sample Use Guides

Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:16:56 GMT 2025
Edited
by admin
on Mon Mar 31 18:16:56 GMT 2025
Record UNII
VRO412Z1ZG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BMS-908662 hydrochloride
Preferred Name English
Code System Code Type Description
FDA UNII
VRO412Z1ZG
Created by admin on Mon Mar 31 18:16:56 GMT 2025 , Edited by admin on Mon Mar 31 18:16:56 GMT 2025
PRIMARY